TwoStep raised a $62.5M Series A backed by Pfizer and Merck KGaA's venture arms to push its peptide-drug conjugate toward Phase 1 this year.
Caitlyn Miller, TwoStep CEO
September 9, 2026 07:00 AM EDT
FinancingStartups
Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
Kyle LaHucik
Pathos AI is raising up to $300M at a ~$3B valuation and inks deals for Alphamab's TROP2/HER3 ADC ($125M upfront) and…
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
Investors have bet new drugs can topple Merck’s Keytruda, but the evidence so far points to something smaller.
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Cartesian’s $150M financing; Editas Medicine’s money moves
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for…
